Co-treatment of SAMC during NAFLD induction significantly reduced the activity of both NF-κB and AP-1, while no obvious effect on the basal activity of these transcription factors was detected (Fig. 6d, f). Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.